ArticleBMC medical genomics2024
Epigenetic age acceleration is associated with blood lipid levels in a multi-ancestry sample of older U.S. adults.
Article in BMC medical genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Epigenetic Age Acceleration and Cardiometabolic Biomarkers in Response to Weight-Loss Dietary Interventions Among Obese Individuals: The MACRO Trial.Aging cell · 2025Trial
- Factors Associated with Machine Learning-Based Predictions of Retinal Aging Using Teleretinal Screening Images from Patients with Diabetes.Ophthalmology science · 2026Article
- Biological aging across the metabolic dysfunction-associated steatotic liver disease spectrum: A systematic review.iLIVER · 2026Review
- Epigenetic Aging Clocks and Incident Cardiovascular Outcomes: Results From the MESA.Journal of the American Heart Association · 2025Article
- Poly-epigenetic scores for cardiometabolic risk factors interact with demographic factors and health behaviors in older US Adults.Epigenetics · 2025Article
- First-generation versus next-generation epigenetic aging clocks: Differences in performance and utility.Biogerontology · 2025Review
- Depressive symptoms partially mediate the relationship between psychosocial factors and epigenetic age acceleration in a multi-racial/ethnic sample of older adults.Brain, behavior, & immunity - health · 2025Article
- Advancing neuroprotection and atherosclerosis prevention through familial hypercholesterolemia management: Analyzing comorbidity burden with stroke, coronary heart disease, hypertension, and diabetes.Neuroprotection (Chichester, England) · 2025Article
- Racial and ethnic differences in epigenetic aging: The National Health and Nutrition Examination Survey, 1999-2002.PloS one · 2025Article
- Associations of epigenetic age acceleration at birth and age 12 years with adolescent cardiometabolic risk: the HOME study.Clinical epigenetics · 2024Article
- Cellular and transcriptomic changes by the supplementation of aged rat serum in human pluripotent stem cell-derived myogenic progenitors.Frontiers in cell and developmental biology · 2024Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
backgroundDyslipidemia, which is characterized by an unfavorable lipid profile, is a key risk factor for cardiovascular disease (CVD). Understanding the relationships between epigenetic aging and lipid levels may help guide early prevention and treatment efforts for dyslipidemia.
methodsWe used weighted linear regression to cross-sectionally investigate the associations between five measures of epigenetic age acceleration estimated from whole blood DNA methylation (HorvathAge Acceleration, HannumAge Acceleration, PhenoAge Acceleration, GrimAge Acceleration, and DunedinPACE) and four blood lipid measures (total cholesterol (TC), LDL-C, HDL-C, and triglycerides (TG)) in 3,813 participants (mean age = 70 years) from the Health and Retirement Study (HRS). As a sensitivity analysis, we examined the same associations in participants who fasted prior to the blood draw (n = 2,531) and in participants who did not take lipid-lowering medication (n = 1,869). Using interaction models, we also examined whether demographic factors including age, sex, and educational attainment modified the relationships between epigenetic age acceleration and blood lipids.
resultsAfter adjusting for age, race/ethnicity, sex, fasting status, and lipid-lowering medication use, greater epigenetic age acceleration was associated with lower TC, HDL-C, and LDL-C, and higher TG (p < 0.05), although the effect sizes were relatively small (e.g., < 7 mg/dL of TC per standard deviation in epigenetic age acceleration). GrimAge acceleration and DunedinPACE associations with all lipids remained significant after further adjustment for body mass index, smoking status, and educational attainment. These associations were stronger in participants who fasted and who did not use lipid-lowering medication, particularly for LDL-C. We observed the largest number of interactions between DunedinPACE and demographic factors, where the associations with lipids were stronger in younger participants, females, and those with higher educational attainment.
conclusionMultiple measures of epigenetic age acceleration are associated with blood lipid levels in older adults. A greater understanding of how these associations differ across demographic groups can help shed light on the relationships between aging and downstream cardiovascular diseases. The inverse associations between epigenetic age and TC and LDL-C could be due to sample limitations or non-linear relationships between age and these lipids, as both TC and LDL-C decrease faster at older ages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.